Advisory panel votes to recommend FDA approval of ticagrelor
Acute Coronary Syndromes
Advisory panel votes to recommend FDA approval of ticagrelor
4 COMMENTS - Jul 28, 2010 17:20 EDT
UPDATED // An FDA advisory panel voted overwhelmingly in favor of approval of AstraZeneca's antiplatelet agent Brilinta for preventing thrombotic events in patients with ACS
Arguments continue over the metabolic syndrome
Features
Arguments continue over the metabolic syndrome
12 COMMENTS - Jul 27, 2010 14:15 EDT
The metabolic syndrome has been the subject of controversy for many years: to this day, agreement cannot be reached between the diabetes and cardiology communities about the validity of naming and treating this clustering of certain risk factors as a separate condition.
Hypertension
FDA approves another triple-drug combination for resistant hypertension: Tribenzor
7 COMMENTS - Jul 26, 2010 14:00 EDT
The new product combines the angiotensin-receptor blocker olmesartan, the calcium-channel blocker amlodipine, and the diuretic hydrochlorothiazide.
heartbriefs
heartbriefs
View all »
Editorial series
A series of discussions among editorial leaders, developed by theheart.org

Japanese perspectives on coronary chronic total occlusions
Editorial series
Japanese perspectives on coronary chronic total occlusions
Jul 19, 2010 09:45 EDT
Dr David Kandzari sits down with Drs Masahiko Ochiai and Etsuo Tsuchikane to discuss when to revascularize and when to opt for bypass surgery, teaching and training, success rates, criteria for selecting antegrade vs retrograde approaches, reasons for failure, and knowing when to halt a procedure.
Editorial series
64-year-old white male referred for transthoracic echocardiography (TTE) due to progressive dyspnea on exertion
3 COMMENTS - Jul 12, 2010 10:35 EDT
Review the echocardiograms and decide which conditions are associated with scleroderma.
The J-curve in hypertension treatment: Fact, fable, relevance?
Editorial series
The J-curve in hypertension treatment: Fact, fable, relevance?
Jul 5, 2010 11:30 EDT
Do data support the concept of the J-curve, the theory that attempting to lower blood pressure beyond a "normal" level constitutes a danger? Drs Jay Cohn, Michael Weber, and Franz Messerli share their thoughts.
Aspirin ad infinitum? Safety and efficacy of daily long-term antiplatelets
Editorial series
Aspirin ad infinitum? Safety and efficacy of daily long-term antiplatelets
2 COMMENTS - Jun 18, 2010 07:00 EDT
Is there evidence to support the long-term use of aspirin and other antiplatelet agents for patients with cardiovascular disease? Join Drs Eric Topol, John Cleland, and Bob Harrington.
Discussion and opinions
Lively, interactive exchanges moderated by thought leaders, staff or contributors to theheart.org

Topolog by Dr Eric Topol
Topolog
Complex trait genomics, or why common gene variants don't fully explain disease
Jul 26, 2010 16:00 EDT
A landmark new study by Dr Robert A Hegele's team explores common and rare variants for hypertriglyceridemia and shows that a combination of multiple rare variants of common genes can help to explain heritability of disease.
theheart.org Forum theheart.org Forum
Discussions among healthcare providers, clinicians, and researchers
Visit the forum »
Lipid/Metabolic
COR-I: Combo drug leads to significant weight loss, but CV effects questioned
Jul 29, 2010 18:30 EDT
New randomized trial results suggest the combination of two "old" drugs might help obese patients lose weight, but one expert worries the blood-pressure effects of the two agents combined need to be taken seriously.
Arrhythmia/EP
Two new randomized trials bolster benefits of compression-only CPR
1 COMMENT - Jul 28, 2010 17:00 EDT
Two large multicenter trials support recent recommendations that bystanders perform hands-only CPR, which can lead to short-term survival rates that are just as good as those with CPR using both chest compressions and mouth-to-mouth breathing. But is the message getting out?
Medscape Medical News
Traditional tools for gauging neurological prognosis post-cardiac arrest may no longer be accurate: Study
Jul 28, 2010 14:45 EDT
Modern care after cardiac arrest, including the widespread use of therapeutic hypothermia, has improved neurologic outcomes so much that traditional prognostic methods may be underestimating survival and the chance for good outcome.
Acute Coronary Syndromes
Taking patients directly to existing PCI centers is more cost-effective than expanding PCI capacity
Jul 28, 2010 10:00 EDT
Computer modeling of different regional approaches to STEMI treatment based on data from Dallas County, TX shows that building an EMS system that can identify STEMI and take patients directly to a PCI -capable center is more cost-effective than expanding PCI capacity.
Murmurs
Dr Terry Ferguson moves on to AstraZeneca
2 COMMENTS - Jul 27, 2010 17:30 EDT
Formerly an academic cardiologist in Texas, Ferguson joined the Medicines Company in January 2008 and has now moved on to be senior director, clinical development, at AstraZeneca. His first focus is ticagrelor, which goes before an FDA advisory panel Wednesday.
Interventional/Surgery
Avoiding lowest-volume centers and adhering to quality measures lower cost of CABG overall
Jul 27, 2010 10:00 EDT
A new study looks at the link between center and surgeon volume and quality of care for coronary bypass surgery.
Acute-MI care at
Interventional/Surgery
Acute-MI care at "high-quality" hospitals as likely for blacks, whites: Medicare data
Jul 26, 2010 16:00 EDT
In an analysis of Medicare data, African Americans were at least as likely as whites to be treated at "America's Best Hospitals" top-ranked for cardiac care when it came to MI, but the story was a bit different regarding admission for CABG.
FDA advisors to contemplate PLATO at July 28 meeting on ticagrelor
Acute Coronary Syndromes
FDA advisors to contemplate PLATO at July 28 meeting on ticagrelor
Jul 26, 2010 15:00 EDT
FDA's Cardiovascular and Renal Drugs Advisory Committee will review AstraZeneca's new drug application for ticagrelor, the proposed new antiplatelet drug for patients with acute coronary syndrome.
Does drinking alcohol temporarily heighten stroke risk?
Medscape Medical News
Does drinking alcohol temporarily heighten stroke risk?
4 COMMENTS - Jul 26, 2010 13:15 EDT
A controversial new study suggests consuming as little as one serving of wine, beer, or hard liquor increases the risk of ischemic stroke.
Medscape Medical News
FDA approves first generic enoxaparin injection
Jul 26, 2010 12:15 EDT
The FDA has approved the first generic formulation of enoxaparin sodium injection, a low-molecular-weight heparin used for multiple indications, including the treatment of acute STEMI and the prevention of ischemic complications from unstable angina and non-Q-wave MI.
Most popular
  1. HF symptom variability more prognostic than severity?
  2. Hope on the horizon for better antidiabetic drugs
  3. Therapeutic window identified for clopidogrel?
  4. Patients with diabetes have alternatives to rosiglitazone, experts say
  5. Half of young adults have CHD risk factors
  6. Boston Scientific safety alert on older ICD models
  7. Triglyceride and waist measurements predict heart-disease risk
  8. Disparities in DES use demonstrated in "real-world" study
  9. More from JUPITER: HDL not predictive of risk at very low LDL levels
  10. Unique study reveals "mosaic" model for triglyceride genetics
View all news »
  1. JUPITER gets a battering, but Ridker fights back
  2. Arguments continue over the metabolic syndrome
  3. More from JUPITER: HDL not predictive of risk at very low LDL levels
  4. Former VP Cheney gets an LVAD
  5. Depression and erectile dysfunction are independent risk factors for heart disease
  6. Patients with diabetes have alternatives to rosiglitazone, experts say
  7. FDA approves another triple-drug combination for resistant hypertension: Tribenzor
  8. Avandia panelists linked to drug makers
  9. Trans fat use "close to zero" in fast-food chains
  10. Does drinking alcohol temporarily heighten stroke risk?
View all discussions »
Poll
Should the FDA halt the TIDE trial (CV safety of rosiglitazone versus pioglitazone)?
See: Rosiglitazone, ticagrelor, dabigatran all up for FDA review this summer
No
Yes

Vote
Membership is free!

The Heart of a Woman
  • Primary and Secondary Prevention of CVD and Stroke in Women
    Primary Prevention in Women: The Role of Lipids
    4 COMMENTS - Jul 2, 2009 00:00 EDT
    The role of lipids in women for primary prevention of cardiovascular disease is a challenging issue for all providers. Join Drs. Foody, Mora, and Welty as they discuss limitations to current risk stratification models, recent clinical trial data, and the changing paradigm in the management of lipids in women.
  • Primary and Secondary Prevention of CVD and Stroke in Women
    All About Eve: The Unique Aspects of CVD in Women
    3 COMMENTS - May 29, 2009 00:00 EDT
    We know there are sex and biological differences in the manifestation of CVD. How do these pathophysiological differences affect the diagnosis and treatment of our female patients? Drs. Hayes, Johnson, Manson, and Piña provide their insight.
View all programs »
Press center
Latest cardiology-related press releases and communications from industry
Also on theheart.org
Transcatheter aortic-valve implantation (TAVI): What does the future hold?
Editorial series
Transcatheter aortic-valve implantation (TAVI): What does the future hold?
Jun 7, 2010 16:50 EDT
Drs Leon, Cribier, Moat, and Ruiz discuss their predictions for new technology, patient selection, the evolving heart-valve team, labs, durability, and more.
What Happened at ACC 2010? A McMaster University Perspective
Educational Partnerships
What Happened at ACC 2010? A McMaster University Perspective
Mar 24, 2010 10:22 EDT
Join Drs. Mehta, Eikelboom, Gupta, and Weitz from McMaster University as they discuss the latest data to come out of the 2010 sessions of the American College of Cardiology in Atlanta, Georgia.
ACC 2010 Review from Atlanta: INVEST, ACCORD, EVEREST II, and NAVIGATOR
The Cardiology Show
ACC 2010 Review from Atlanta: INVEST, ACCORD, EVEREST II, and NAVIGATOR
3 COMMENTS - Mar 17, 2010 16:25 EDT
Dr Valentin Fuster sits down with Drs Peter Berger, Anne Curtis, Tim Gardner, Tony Gershlick, Harlan Krumholz, Darren McGuire, Ileana Piña, and Rita Redberg to discuss the lessons learned at the ACC 2010 Scientific Sessions, including why lower may not be better for blood pressure, why preventing diabetes does not necessarily reduce cardiovascular risk, and the future of the mitral-valve clip.